The Board of Directors of Gland Pharma has approved the acquisition of 100 per cent of the equity share capital of Gland Pharma USA Inc. a wholly-owned step-down subsidiary of the Company, from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company.
The board meeting was held on Sunday. Accordingly, upon completion of the acquisition, Gland US will become a direct wholly-owned subsidiary of the Hyderabad-based Gland Pharma.
The cost of acquisition was pegged at about $5 lakh in cash consideration, the BSE was informed on Tuesday.
The Company’s management has proposed to make Gland US a direct wholly-owned subsidiary (from it being a step-down wholly-owned subsidiary) to remove multiple layers and streamline the corporate structure. “There is no material impact on the business or operations of the company,” it said.
The principal activity of Gland US is marketing and distribution of pharmaceutical products.
Published on September 15, 2026
